Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ED Drug Labeling Revised For Potential Risk Of Hearing Loss

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA identifies 29 postmarketing reports of sudden hearing loss in patients using PDE 5 inhibitors, including Cialis, Levitra and Viagra.

You may also be interested in...



FDA Alters Levitra, Effexor XR Labels

Erectile-dysfunction package insert will now note phenomenon of sudden temporary memory loss.

FDA Alters Levitra, Effexor XR Labels

Erectile-dysfunction package insert will now note phenomenon of sudden temporary memory loss.

Viagra Non-Prescription Switch Would Face High Bar For Safety

Inappropriate selection, intentional or unintentional off-label use could exacerbate concerns like blindness, drug interactions, according to some experts.

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel